$69.22
Value $7.4B
CORT and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$69.22
Value $7.4B
$144.46
Value $357B
Corcept Therapeutics (CORT) has a market value of $7.4B and Merck & Company (MRK) $357B. Over the last year, with dividends, CORT moved -8.4% and MRK +60.0%. The P/E is 46.2 for CORT and 145.6 for MRK. Dividend yield: CORT none, MRK 2.35%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CORT$7.4B
MRK$357B
MRK is 49 times CORT
Revenue, 12 months
CORT$964M
MRK$67.4B
MRK is 70 times CORT
Net income, 12 months
CORT$162M
MRK$2.5B
MRK is 15 times CORT
Operating margin
CORT11.5%
MRK–
ROIC
CORT12.7%
MRK3.9%
8.8 points apart
P/E
CORT46.2
MRK145.6
MRK is 3.2 times CORT
Dividend yield
CORT0.0%
MRK2.4%
2.4 points apart
5-year return
CORT+202.4%
MRK+101.1%
101.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CORT+202.4%
MRK+101.1%
| Period | CORTWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -8.4%Price -8.4% | +60.0%Price +55.5% |
| 3 years since November 16, 2023 | +175.7%+40.2% a yearPrice +175.7% | +55.2%+15.8% a yearPrice +41.6% |
| 5 years since November 15, 2021 | +202.4%+24.8% a yearPrice +202.4% | +101.1%+15.0% a yearPrice +72.6% |
| 10 years since November 16, 2016 | +631.7%+22.0% a yearPrice +631.7% | +228.0%+12.6% a yearPrice +141.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CORTCorcept TherapeuticsMRKMerck & Company
| Price | $69.22 | $144.46 |
|---|---|---|
| Market value | $7.4B | $357B |
| Enterprise value (EV) | $7.0B | $401B |
| P/E | 46.2 | 145.6 |
| P/E, 5-year median | 34.6 | 14.8 |
| P/B | 8.8 | 8.0 |
| EV/EBIT | 63.1 | 84.3 |
| Free cash flow yield | 2.6% | 4.1% |
| Revenue, 12 months | $964M | $67.4B |
|---|---|---|
| Net income, 12 months | $162M | $2.5B |
| Free cash flow, 12 months | $195M | $14.7B |
| Earnings per share, 12 months | $1.50 | $0.98 |
| Revenue growth, year on year | 12.8% | 1.3% |
| Revenue growth a year, past | +16.6%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | -0.7%over 5 years | +21.2%over 5 years |
| Gross margin | 98.5% | 71.8% |
|---|---|---|
| Operating margin | 11.5% | – |
| Net margin | 16.8% | 3.6% |
| ROIC | 12.7% | 3.9% |
| ROE | 23.5% | 5.2% |
| Cash | $371M | $9.7B |
|---|---|---|
| Total debt | $9.0M | $53.8B |
| Net debt / EBITDA | -3.3 | 5.7 |
| Interest cover | – | 2.4× |
| Dividend yield | – | 2.4% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | 2.4% | 1.4% |
| Shareholder yield | 2.4% | 3.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($357B) is about 48.5 times Corcept Therapeutics ($7.4B), at today's prices.
Since November 16, 2016, CORT's price moved +631.7% and MRK's +141.7%. With dividends: CORT +631.7% (+22.0% a year), MRK +228.0% (+12.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Corcept Therapeutics and 2.35% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 46.2 for CORT and 145.6 for MRK. The median of the last five years was 34.6 and 14.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 16.8% for Corcept Therapeutics and 3.6% for Merck & Company, and the operating margin 11.5% and –. Revenue was $964M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.